More than just storage

Early obesity models taught us that adipocytes simply store lipids until needed. But that’s only part of the story. We now know adipocytes behave more like endocrine cells: releasing hormones, cytokines, and danger signals that influence systemic metabolism and immune activity¹. When adipocytes grow too large, through hypertrophy and hyperplasia, they can become hypoxic and stressed. This triggers a local immune response, drawing in macrophages and other immune cells. Far from being a metabolic sideshow, this immune activity plays a central role in obesity’s complications².

Macrophages in fat tissue

In lean adipose tissue, immune cells help maintain homeostasis, but in obesity, the balance tips. Enlarged adipocytes secrete chemokines like MCP-1, recruiting monocytes that differentiate into pro-inflammatory (M1) macrophages³. These macrophages cluster around dead or dying adipocytes in crown-like structures⁴, which can be seen in stained tissue sections.

The result? A self-sustaining loop. Adipocytes signal distress, and macrophages respond with TNF-α, IL-6, and IL-1β, further disrupting insulin signaling and adipocyte function⁵. Over time, this low-grade inflammation spills beyond the tissue, contributing to insulin resistance, type 2 diabetes, and cardiovascular disease⁶.

Key molecular players

Whether you’re modeling adipogenesis, studying insulin resistance, or characterizing inflammation in vitro, certain markers keep coming up. Leptin, TNF-α, IL-6, and PPARγ are central to how obesity progresses and how we might treat it. These molecules serve as mechanistic markers,  potential therapeutic targets, and functional readouts in in vitro inflammation assays:

Understanding what these molecules do in the context of obesity and how they behave in models can help researchers more effectively troubleshoot experiments, interpret signaling shifts, and design studies that reflect real-world complexity.

Modeling inflammation in obesity

Traditional 2D adipocyte cultures are useful but limited, especially when it comes to modeling immune interactions. In reality, inflamed fat is a complex, multicellular environment. Adipocytes interact dynamically with immune cells, fibroblasts, and vasculature, and these interactions shape inflammation, metabolism, and differentiation outcomes. That’s why researchers are increasingly turning to models that better capture the structure, signaling, and immune context of adipose tissue, such as:

●       Human iPSC-derived adipocytes: These cells retain donor-specific traits and allow for studies of adipogenesis, cytokine release, and gene editing under physiologically relevant conditions¹¹.

●       Adipose organoids: These offer a 3D structure and include stromal components like fibroblasts and vascular cells. They can mimic depot-specific characteristics (e.g., visceral vs. subcutaneous fat) and show more realistic cytokine profiles¹².

●       3D co-cultures with macrophages: These cultures can recreate immune–adipocyte interactions¹³.

These advanced models are helping researchers more accurately replicate the immune–metabolic environment of adipose tissue, to reveal new therapeutic opportunities and biomarkers of disease progression.

What blood biomarkers and new drugs are teaching us

Obesity’s inflammatory footprint isn’t just local. Clinical studies regularly track systemic markers like CRP, IL-6, and leptin to monitor metabolic risk. These fluid biomarkers reflect the state of adipose inflammation and are now used to assess therapeutic efficacy.

GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) were initially designed for diabetes. However, these drugs have now been shown to drive significant weight loss and lower systemic inflammation. Trials show drops in CRP and IL-6 levels alongside improved insulin sensitivity¹⁴. It’s a reminder that interventions targeting metabolism can – and likely will – also modulate immune tone.

Obesity as an immune–metabolic condition

The more research into adipocytes advances, the more we can be sure that obesity isn’t just about lipid storage. It’s an immune–metabolic disorder that merges endocrinology, immunology, and systems biology. That shift matters not just for how we treat obesity, but also for how we connect research within the lab.

Researchers working with cytokines, differentiation markers, or inflammation assays may find their insights overlap with obesity research, and understanding how adipose tissue shapes systemic inflammation may make their research more relevant. Obesity research might not be your primary research focus, but if you’re studying inflammation, signaling, or cellular stress, you’re already part of the story.

References

1. Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat.  Cell  156, 20–44 (2014).
2. Cao, Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases.  Nat. Rev. Drug Discov.  9, 107–115 (2010).
3. Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization.  J. Clin. Invest.  117, 175–184 (2007).
4. Cinti, S.  et al.  Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans.  J. Lipid Res.  46, 2347–2355 (2005).
5. Hotamisligil, G. S. Inflammation and metabolic disorders.  Nature  444, 860–867 (2006).
6. Engin, A. The pathogenesis of obesity-associated adipose tissue inflammation. In  Obesity and Lipotoxicity  (eds Engin, A. B. & Engin, A.) 221–245 (Springer, 2017).
7. La Cava, A. & Matarese, G. The weight of leptin in immunity.  Nat. Rev. Immunol.  4, 371–379 (2004).
8. Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function.  Nature  389, 610–614 (1997).
9. Kristiansen, O. P. & Mandrup-Poulsen, T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?  Diabetes   54  Suppl 2, S114–S124 (2005).
10. Tontonoz, P. & Spiegelman, B. M. Fat and beyond: the diverse biology of PPARγ.  Annu. Rev. Biochem.  77, 289–312 (2008).
11. Keidai, Y., Fujikura, J. & Yabe, D. Application of human iPSC-derived white, beige, and brown adipocytes for metabolic disease modeling and transplantation therapy.  Cell Transplant.  34, 09636897251346599 (2025).
12. Robledo, F.  et al.  Spheroids derived from the stromal vascular fraction of adipose tissue self-organize in complex adipose organoids and secrete leptin.  Stem Cell Res. Ther.  14, 70 (2023).
13. Dal-Mora, T.  et al.  Pre-adipocytes in 3D co-culture underwent self-differentiation: new perspectives for an old model.  Organoids  3, 295–308 (2024).
14. Alharbi, S. H. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.  Ther. Adv. Endocrinol. Metab.  15, 20420188231222367 (2024).